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Vascular disease remains a major cause of mor-
bidity and death in the United States. Numerous
interventions (such as bypass grafting, endarterecto-
my, and angioplasty) have been used for the treat-
ment of peripheral vascular disease; however, the
long-term patency of these procedures is compro-
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Purpose: Although 60% to 80% of the mature intimal hyperplastic plaque is composed of
extracellular matrix (ECM) proteins, little is known about the factors that stimulate
smooth muscle cells (SMCs) to produce these proteins. A major component of the ECM
protein is fibronectin. Thus we studied fibronectin production and its response to vari-
ous growth factors, cytokines, and other ECM proteins that are released at the time of
vascular injury.
Methods: Quiescent cultured human SMCs were stimulated for varying intervals with
increasing concentrations of agonist. Fibronectin in the cell medium was assayed by
immunoblotting with a fibronectin-specific antibody.
Results: After 72 hours of stimulation, transforming growth factor-β (10 ng/mL) had
the most profound effect on fibronectin production (9.6- ± 2.1-fold; P < .05), followed
by epidermal growth factor (100 ng/mL; 5.0- ± 0.1-fold; P < .05, for both).
Surprisingly, the platelet-derived growth factors (AA, AB, and BB) and fibroblast
growth factor did not stimulate fibronectin production. Among the matrix proteins
studied, only collagen type I (20 µg/mL) stimulated fibronectin production (1.9- ± 0.1-
fold; P < .05), whereas collagen type IV and laminin had no effect. The contractile pro-
tein angiotensin II (100 ng/mL) was a weak stimulant of fibronectin (1.6- ± 0.2-fold;
P < .05). Time course studies of fibronectin production up to 72 hours revealed kinet-
ics that varied with each agonist. Transforming growth factor-β stimulated significant
early production of fibronectin, whereas fibronectin production in response to epider-
mal growth factor and collagen type I was initially modest but increased with time. The
effect of angiotensin II did not become evident until 72 hours. 
Conclusion: Cytokines, growth factors, and matrix proteins have varying quantitative
effects on ECM protein production by human vascular SMCs. Knowledge of the factors
that influence ECM protein production may allow for the design of specific inhibitors
that can prevent intimal hyperplasia. (J Vasc Surg 2000;31:577-84.)
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mised in up to 50% of cases by a pathologic process
known as intimal hyperplasia.1,2 The three key
events in the formation of intimal plaque after vas-
cular injury are vascular smooth muscle cell (SMC)
migration, proliferation, and extracellular matrix
(ECM) protein production.3
Although there has previously been great
emphasis on the study of SMC proliferation and
migration, the importance of ECM proteins in the
formation of intimal plaque is less well understood.
From the standpoint of volume, ECM proteins are
clearly essential because 60% to 80% of a mature inti-
mal plaque is composed of these proteins.4,5 It is
also now realized that ECM proteins have numerous
pathophysiologic actions that may potentially pro-
mote a hyperplastic response. Studies from this lab-
oratory reveal that the ECM proteins (collagen type
I and IV, laminin, and fibronectin) can stimulate vas-
cular SMC migration.6 Additional studies have
proved a role for these same proteins in SMC prolif-
eration.7 Thus ECM proteins are critically important
in the development of intimal hyperplasia both
because of their contribution to plaque volume and
because of their potential to activate SMCs.
Fibronectin is a high molecular weight glycopro-
tein that is present in normal arteries and is an abun-
dant component of the ECM protein of intimal
plaque.4,8 Its structure is that of a dimer, with 220
kD and 250 kD subunits attached by a disulfide
bond.9 Fibronectin is produced by endothelial cells
and SMCs and therefore is found both in the base-
ment membrane and the interstitial matrix sur-
rounding SMCs.10 It has been well established that
fibronectin is released into intimal plaque after vas-
cular injury. Using a balloon catheter injury model
with rodent carotid arteries, Majesky et al8 found an
increase in fibronectin messenger RNA transcripts in
neointimal SMCs at 6 hours, maximal transcription
on day 7 after injury, and a decrease to baseline lev-
els by 30 days.
The factors that lead to this increase in
fibronectin transcription have not been studied in
any detail. Boudreau et al11 and Clausell et al12 have
studied the effect of transforming growth factor-β
(TGF-β), IL-1β, and TNF-α on fibronectin produc-
tion in human pulmonary, porcine, and fetal lamb
SMCs. However, vascular injury after arterial recon-
struction is associated with the release of multiple
other growth factors that have the potential to affect
SMC behavior. Platelet-derived growth factor
(PDGF) is a potent mediator of both SMC migra-
tion and proliferation.13,14 Epidermal growth factor
(EGF), fibroblast growth factor (FGF), and
angiotensin II all have a stimulatory effect on SMC
proliferation.15 TGF-β has an inhibitory effect on
these two cellular events.15 Despite their known
effects on SMC proliferation and migration, the
influence of these same factors on production of
matrix proteins, specifically fibronectin, has been less
well evaluated.
In the following study, we assess the effect of a
variety of growth factors, cytokines, and ECM pro-
teins on fibronectin production in human vascular
SMCs. We found that TGF-β and EGF were the most
potent agonists of fibronectin. Although several other
agonists stimulated production of fibronectin, we
were surprised to find that the potent growth factors
PDGF and FGF had no effect on the release of this
matrix protein.
MATERIAL AND METHODS
General materials. Human recombinant PDGF-
AA, AB, and BB, FGF, and EGF were obtained from
Upstate Biotechnologies, Inc (Lake Placid, NY).
TGF-β was obtained from R & D Systems
(Minneapolis, Minn). Angiotensin II, collagen type I
from calf skin, collagen type IV from human placen-
ta, laminin from the basement membrane of
Engelbreth-Holm-Swarm mouse sarcoma, smooth
muscle–specific actin immunostaining kit, ethylene
glycol-bis(b-aminoethyl ether)-N,N,N´,N´-tetra-
acetic acid (EGTA), ethylenediaminetetraacetic acid
(EDTA), phenylmethylsulfonyl fluoride (PMSF),
sodium dodecyl sulfate (SDS), Nonidet-P40, and
Triton X-100 were from Sigma Chemical Co (St
Louis, Mo). Dulbecco’s Modified Eagle’s Medium
high glucose (DMEM-Hg), phosphate-buffered
saline solution, fetal bovine serum, trypsin-EDTA,
penicillin/streptomycin/amphotericin B solution, L-
glutamine, and N-2-Hydroxyethylpiperazine-N´-2-
ethanesulfonic acid (HEPES) were from Gibco BRL
(Gaithersberg, Md). The enhanced chemilumines-
cence system was from Amersham Life Science Inc
(Little Chalfont, UK). Mouse monoclonal anti-
human fibronectin antibody was obtained from
Calbiochem (San Diego, Calif).
Cell culture. SMCs were derived from a cell line
previously isolated from a human carotid
endarterectomy specimen.16 SMCs seeded onto tis-
sue culture plates were maintained at 37°C and 5%
carbon dioxide in DMEM-Hg supplemented with
10% fetal bovine serum, 25 mmol/L HEPES, 40
U/mL penicillin G, 40 µg/mL streptomycin, 100
ng/mL amphotericin B, and 4.8 mmol/L L-gluta-
mine. SMC identity was verified by immunostaining
with anti-human α-actin antibody and by a charac-
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teristic “hill and valley” growth pattern. These find-
ings verify that the cells used in this study were
smooth muscle/myofibroblast in nature; however,
the possibility that the cells were derived from the
adventitia rather than the neointima cannot be
excluded.
Fibronectin assay by immunoblotting. T-60
plates were seeded with SMCs and grown to conflu-
ence in media containing 10% serum. Cells were
starved for 24 hours in serum-free media and then
stimulated with agonists for the desired periods of
time. For measurement of fibronectin in the cell
media, 500 mL samples were diluted 1:5 in DMEM
and centrifuged at 1600 rpm for 6 minutes. For
determination of fibronectin in the cell lysates, cell
media were removed completely, and the cell layers
were washed with ice cold phosphate-buffered saline
solution. SMCs were then lysed in radioimmunopre-
cipitation assay buffer (10 mmol/L Tris-HCl pH
7.5, 150 mmol/L NaCl, 0.5 % Nonidet P-40, 1.0 %
Triton X-100, 50 mmol/L NaF, 1.0 mmol/L
EGTA, 1.0 mmol/L EDTA, 0.5 mmol/L PMSF,
and 0.5 mmol/L sodium orthovanadate). Next,
lysates were centrifuged at 1500 rpm for 20 minutes
at 4°C. Total protein concentrations were measured
in the supernatant by a modification of the method
of Lowry, and protein amounts for the samples were
equalized. Samples from both the cell media and the
cell lysates were diluted 1:2 in Laemmli sample
buffer, boiled at 100°C for 10 minutes, and then
subjected to SDS-polyacrylamide gel electrophore-
sis, with equal protein amounts loaded into each of
the lanes. The electrophoretically separated proteins
were transferred to a polyvinylidene difluoride mem-
brane then, after blocking, incubated with a primary
antibody specific for fibronectin followed by a horse-
radish peroxidase-conjugated secondary antibody.
Labeled proteins were visualized with an enhanced
chemiluminescence system. Blots were quantitated
with densitometry by Eagle Eye I (Stratagene, La
Jolla, Calif). Data sets were created by direct com-
parison between the lanes of each blot. Results were
expressed as fold increase in fibronectin production
compared with control. Controls were SMCs incu-
bated for the designated period of time in the
absence of the agonist being tested.
Cell counting. For the evaluation of changes in
cell number in response to the various agonists, at
72 hours after removal of cell media, SMCs were
removed from T-60s by trypsinization. Ten-micro-
liter samples of the cell suspension were diluted 1:20
with DMEM; cell counting was performed with a
hemocytometer.
Statistical analysis. All experiments were per-
formed at least three times. Results were expressed as
a fold increase in fibronectin production (agonist vs
vehicle-stimulated cells). The overall differences in
fold induction of fibronectin production among vari-
ous time points were first analyzed with one-way
analysis of variance (ANOVA). Comparisons between
individual time points were assessed with t tests based
on the least significant difference method for
ANOVA. Similarly, the overall difference in potency
among various agonists at 72 hours was first analyzed
by one-way ANOVA. Differences between individual
agonists were assessed with t tests based on the least
significant difference method for ANOVA. A proba-
bility value of less than .05 was considered a significant
difference.
RESULTS
Fibronectin production
Concentration response. We first measured
fibronectin production in the cell medium 72 hours
after stimulation of SMCs with increasing concentra-
tions of the various agonists. Concentration-depen-
dent increases in fibronectin were observed when
SMCs were stimulated with TGF-β, EGF, collagen
type I, and angiotensin II (Fig 1, A). Concentrations
of the stimulatory agonists that produced maximal
fibronectin production were TGF-β (10 ng/mL),
EGF (100 ng/mL), collagen type I (20 µg/mL),
and angiotensin II (100 ng/mL). Higher concentra-
tions of each of these agonists did not further
enhance the production of fibronectin. Surprisingly,
the potent mediator of SMC migration and prolifer-
ation, PDGF-BB, had no effect on fibronectin pro-
duction at concentrations up to 20 ng/mL (Fig 1,
B). PDGF AA and AB had no effect on fibronectin
production at similar concentrations (data not
shown). Moreover, FGF had no effect on fibronectin
at concentrations up to 1000 ng/mL. The ECM
proteins, collagen type IV and laminin, were likewise
ineffective in stimulating fibronectin production at
concentrations up to 50 ng/mL. 
Fibronectin was then measured in the SMC
lysate. TGF-β was the only agonist that stimulated a
detectable increase in fibronectin (data not shown).
This effect was concentration dependent and
reached a maximum at 10 ng/mL. 
Levels of fibronectin were not related to changes
in cell number because there was no statistical dif-
ference in cell numbers over the 72-hour period of
stimulation for any of the agonists studied. The lack
of an effect of these growth factors on SMC prolif-
eration was surprising and may have been related to
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the fact that the SMCs were in a confluent state
before the initiation of these experiments.
Time course. We next evaluated, for the four
positive agonists, their effect on fibronectin produc-
tion over time. Using the concentrations of agonists
that produced maximal stimulation at 72 hours, we
evaluated the rate of fibronectin production over 3
consecutive days. For these experiments, vehicle-
treated controls and agonist-treated plates were pre-
pared in a similar fashion for each time point. The
effect of each agonist on fibronectin production was
expressed as fold increase in fibronectin production
(agonist vs vehicle control) at each of time point (ie,
0, 24, 48, and 72 hours). Interestingly, the kinetics of
fibronectin production were different for each of the
four positive agonists (Fig 2). For TGF-β, a statisti-
cally significant increase in fibronectin was evident at
24 hours (5.4- ± 1.4-fold increase; P < .05); the quan-
tity of fibronectin further increased at 48 hours (8.2-
± 2.1-fold). There was no further statistical increase in
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Fig 1. Fibronectin production in quiescent cultured human vascular SMCs after 72 hours of
stimulation with increasing concentrations of (A) TGF-β, EGF, collagen type I, and
angiotensin II (AT II) or (B) PDGF-BB, FGF, collagen type IV, and laminin. Fibronectin was
assayed in the cell medium with the use of an antibody specific for the 220 kD subunit. All
experiments were repeated at least three times, and a representative example is displayed.
A
B
fibronectin at 72 hours (Table I). For EGF, there was
a modest but statistically significant increase in
fibronectin production at 24 hours on day 1 (2.2- ±
0.5-fold; P < .05); however, further statistically signif-
icant increases in fibronectin were evident at 48 and
72 hours (P < .05 for all comparisons; Table I). The
pattern for collagen type I was similar to that of EGF.
For angiotensin II, the effect on fibronectin produc-
tion did not become statistically significant until 72
hours (Table I).
Comparison of agonists. In a final series of
experiments, we compared the potency of the four
positive agonists as stimulants of fibronectin produc-
tion at 72 hours. TGF-β (10 ng/mL) had the most
profound effect on fibronectin production with a
9.68- ± 2.13-fold increase over the unstimulated con-
trol (P < .05; Fig 3). EGF (100 ng/mL) had an effect
that was approximately one half that of TGF-β with a
5.01- ± 0.1-fold increase over control (P < .05, com-
parison to TGF-β). Collagen type I (20 µg/mL) and
angiotensin II (100 ng/mL) stimulated fibronectin
to a much lesser extent (1.9- ± 0.1-fold and 1.6- ±
0.2-fold, respectively; P < .05 for comparison of both
to EGF). There was no significant difference in the
amount of fibronectin stimulated by collagen type I
and angiotensin II. 
DISCUSSION
After vascular injury, intimal expansion depends
not only on SMC proliferation and migration but,
perhaps more significantly, on ECM protein produc-
tion. Although, SMC migration and proliferation
occur early after arterial injury, the bulk of intimal
plaque is formed at a point after these two processes
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Fig 2. Fibronectin production in quiescent cultured human vascular SMCs at 0, 24, 48, and
72 hours after stimulation with TGF-β, EGF, collagen type I, or angiotensin II (AT II; right
panel) and their respective vehicle controls (left panel). Fibronectin was assayed in the cell
medium with the use of an antibody specific for the 220 kD subunit of fibronectin. All exper-
iments were repeated at least three times, and a representative example of each is displayed.
Table I. Fold increase in fibronectin production stimulated by agonists*
0 h (n = 6) 24 h (n = 3) 48 h (n = 3) 72 h (n = 6)
TGF-β 1.1 ± 0.2 5.1 ± 1.4† 8.2 ± 2.1† 9.6 ± 2.1†
EGF 1.3 ± 0.3 2.2 ± 0.5† 3.6 ± 0.2† 5.0 ± 0.1†
Collagen I 1.0 ± 0.1 1.2 ± 0.1† 1.6 ± 0.2† 1.9 ± 0.1†
Angiotensin II 1.0 ± 0.2 1.1 ± 0.2 1.2 ± 0.2 1.6 ± 0.2†
*Fibronectin production ± SD in human vascular SMC at 0, 24, 48, and 72 hours after stimulation with TGF-β (10 ng/mL), EGF (100
ng/mL), collagen type I (20 mg/mL), or angiotensin II (100 ng/mL) expressed as fold increase above control. 
†P < .05, comparison to the 0-hour time point.
have subsided. The result is a mature lesion, with
60% to 80% of its composition being ECM pro-
tein.4,5 Many researchers have studied the effect of
growth factors, cytokines, and ECM proteins on
SMC migration and proliferation; however, the
effect of these agonists on SMC ECM protein pro-
duction has been less well evaluated.
TGF-β is the most potent stimulant of fibronectin
production in human SMCs. This effect is consistent
with the recognized ability of TGF-β to stimulate the
production and release of matrix proteins. In almost
every human organ affected by a fibrogenic disease,
TGF-β is a major stimulant of excess ECM protein.17
For example, TGF-β is instrumental in the formation
of both liver fibrosis and glomerulosclerosis in
humans through its effects on myofibroblasts and
mesangial cells.18,19 The critical role of TGF-β in the
process of intimal hyperplasia has been well estab-
lished. TGF-β mRNA transcripts are increased in both
experimental intimal hyperplastic and human
restenotic lesions.8,20 Moreover, the addition of
exogenous TGF-β enhances intimal thickening after
vascular injury in rabbit carotid arteries.21 Because
TGF-β has a known inhibitory effect on SMC migra-
tion and proliferation,22 the provocative effect of this
cytokine on intimal hyperplasia may be largely related
to its to stimulatory effect on ECM protein produc-
tion. Our data regarding the ability of TGF-β to stim-
ulate the release of fibronectin from SMCs lend sup-
port to this hypothesis. Interestingly, TGF-β was the
only agonist to produce a rise in intracellular
fibronectin. The relevance of this finding is unclear
but may be related to the dramatic increase in
fibronectin synthesis induced by TGF-β, with the
achievement of a new intracellular steady state. 
In SMCs, EGF stimulates both replication and
migration, although to a lesser extent than PDGF.15
To our knowledge, we are the first to report a role for
EGF in ECM protein production in human SMCs.
Studies that define the role of EGF in the develop-
ment of intimal plaque are not available, although
EGF is produced by both SMCs and macro-
phages.23,24 The very potent effect of EGF on
fibronectin production relative to the other agonists
tested, coupled with its effect on SMC migration and
proliferation, suggests that the contribution of this
growth factor to the hyperplastic process may be sig-
nificant. EGF has been found to have a stimulatory
effect on fibronectin production in other cell types,
such as cultured rat liver epithelial cells, and mouse
fibroblast cells.25,26 Moreover, EGF stimulates other
ECM proteins such as collagen in rabbit fibroblasts.27
The effect of EGF on collagen production in human
SMCs is unknown but may also be relevant in the
pathophysiologic features of intimal hyperplasia.
ECM proteins are abundant in the vascular milieu
after arterial injury.28 Accordingly, we questioned
whether other matrix proteins might affect fibronectin
production in either a positive or negative manner. We
studied the effect of several matrix proteins that are
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Fig 3. Fold increase ± SD in fibronectin production in quiescent cultured human vascular
SMCs after 72-hour stimulation with TGF-β (10 ng/mL), EGF (100 ng/mL), collagen type
I (20 µg/mL), or angiotensin II (AT II; 100 ng/mL). Fibronectin was assayed in the cell
medium with the use of an antibody specific for the 220 kD subunit of fibronectin. All exper-
iments were repeated at least three times. *P < .05 vs control.
produced in response to arterial injury on SMC
fibronectin production. Collagen type IV and laminin
did not influence fibronectin production in all con-
centrations tested. However, collagen type I, which is
the matrix protein that is most prevalent in atheroscle-
rosis or intimal plaque, had a modest but significant
stimulatory effect on fibronectin production. This is a
relevant finding because we have previously found that
this same matrix protein stimulates SMC migration
and proliferation.6,7 Moreover, the effect of collagen
type I on migration and proliferation is synergistically
enhanced when SMCs are stimulated simultaneously
with collagen type I and PDGF.7 Therefore collagen
type I has the potential to promote all three critical
events that lead to the development of intimal hyper-
plasia. In contrast to our findings, other investigators
have shown that collagen in some cell types can inhib-
it the release of cellular fibronectin.29-31 Thus the
effect of collagen type I on fibronectin production
appears to be cell specific.
We found that the contractile agonist, angiotensin
II, has a weak stimulatory effect on fibronectin pro-
duction in human vascular SMCs. A similar finding
has previously been reported in rat aortic SMCs.32
Both angiotensin II and its activator angiotensin con-
verting enzyme (ACE) have been implicated in intimal
hyperplasia. In a rabbit vein graft model of vascular
injury, levels of ACE are elevated 14 days after bypass
grafting.33 Systemic inhibition of ACE has been found
to produce a significant reduction in the formation of
hyperplastic plaque after injury in a rat carotid artery.34
Although the role of angiotensin II in intimal hyper-
plasia is at least in part related to its ability to stimulate
SMC proliferation,35 our data suggest that angio-
tensin II may simultaneously enhance this process by
stimulating SMCs to release fibronectin.
Our studies of cultured human vascular SMCs
demonstrate no increase in fibronectin production
with any of the three PDGF isotypes. PDGF is a
potent agonist of SMC migration and proliferation,
and we were surprised to find that this growth factor
had no effect on fibronectin.13,14 Others investigators,
using different cell types, have observed a positive
influence of PDGF on fibronectin production. PDGF
stimulates fibronectin mRNA in cultured mouse
embryo fibroblasts and cultured human mesangial
cells.18,36 In contrast, PDGF-BB in cultured rat
myoblasts only slightly increased fibronectin secretion
with concentrations up to 100 ng/mL.37 Differences
in cell type and species may account for the disparity
between our results and those of others. PDGF does
appear to consistently stimulate the production of col-
lagen in vascular SMCs.38 Thus at least some ECM
proteins are affected by this relevant growth factor.
FGF, another potent agonist of SMC proliferation,
also had no effect on fibronectin production despite
our use of concentrations up to 1000 ng/mL. In gen-
eral, the role of FGF in ECM protein production by
SMCs has not been well investigated. However, in
other cells studied, FGF does not appear to have a
stimulatory effect on matrix protein synthesis.39
There appears to be a correlation between the time
course of TGF-β, collagen type I, and angiotensin II
release after vascular injury and the release of
fibronectin. Levels of the cytokine TGF-β remain ele-
vated for more than 2 weeks after arterial injury.8 Thus
TGF-β is indeed available at the time during which
fibronectin transcription and production occur (1-30
days).8 This is also true for angiotensin II and collagen
type I. The transcription of angiotensin II is maximal
at 7 days, which coincides with maximal transcription
of fibronectin; and the transcription of collagen peaks
at 2 weeks and persists for at least 4 weeks after
injury.28,40
ECM proteins such as fibronectin are essential
components of intimal plaque. Although fibronectin
does contribute to plaque volume, this contribution is
much less than that of collagen type I.3 The greatest
importance of fibronectin in intimal hyperplasia may
be related to the potential for this matrix protein to
stimulate SMC migration and proliferation. In these
studies, we have found that TGF-β and EGF are the
most potent agonists of fibronectin production in
human vascular SMCs. The ECM protein, collagen
type I, and the contractile agonist, angiotensin II, also
stimulate the release of fibronectin but to a much less-
er extent. The role of these same agonists in the pro-
duction of other important matrix proteins, such as
collagen type I and IV, has not yet been determined.
However, the effect of these agonists on ECM pro-
tein production will need to be fully evaluated before
the process of intimal hyperplasia can be completely
understood.
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